Skip to main navigation
News
Contact
Company
About Us
Leadership Team
Board of Directors
Collaborations
State Regulations/Disclosures
Contact
Our Focus
Structure-Guided Drug Design
Rare Disease Therapeutics
Our Products
ORLADEYO® (berotralstat)
ORLADEYO® Prescribing Information
RAPIVAB
®
(peramivir injection)
Our Programs
Pipeline
Complement Program
FOP Program
Galidesivir
Medical Affairs
Request for Medical Information
Request for Medical Education Grants
External Research Grants
Expanded Access Program/Policy
Clinical Trial Data Transparency
Careers
Career Openings
Culture
Investors & Media
Corporate Profile
Analyst Coverage
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Stock Lookup
Investment Calculator
Finance & Filings
Financial Profile
SEC Documents
Corporate Governance
Highlights
Committee Composition
Code of Business Conduct
Committee Charters
Investor FAQs
Proxy Online
News
Contact
Investors & Media
Corporate Profile
Analyst Coverage
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Stock Lookup
Investment Calculator
Finance & Filings
Financial Profile
SEC Documents
Corporate Governance
Highlights
Board of Directors
Committee Composition
Code of Business Conduct
Committee Charters
Investor FAQ
Proxy Online
Investor Relations
John Bluth
+1 919.859.7910
investorrelations@biocryst.com
Investor Tools
Shareholder Tools
Print Page
Printed Materials
Email Alerts
RSS News Feeds
Share Page
Event Details
BCX9250 Phase 1 Results
Dec 21, 2020
Facebook
GOOGLE
LINKEDIN
TWITTER
RSS
